Fierce Biotech12d
AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...
Foxo Technologies signs non-binding agreement to acquire Vector Biosource
FOXO Technologies (FOXO) has signed a non-binding agreement to acquire Vector Biosource. Vector is an information and biospecimen sourcing ...
Asian News International on MSN9d
Bharat Biotech launches India's only integrated cell, gene therapy, and viral production facility
Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...
Bharat Biotech sets up $75 million integrated Cell and Gene Therapy, viral production facility in Hyderabad
Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...
Nature10d
The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain
1B). In all cases, the flap sequence significantly enhanced GFP transduction mediated by the HIV vector. Figure 1: The HIV-1 central DNA flap enhances gene transduction of primary neural cells.
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON BINDING AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
Myrtle Recovery Centers, Inc., a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT ...
Bharat Biotech launches India's only integrated cell, gene therapy facility
BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies ...